# reload+after+2024-01-23 03:45:41.472671
address1§1111 Lincoln Road
address2§Suite 500
city§Miami Beach
state§FL
zip§33139
country§United States
phone§702 514 4174
website§https://www.pasithea.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
fullTimeEmployees§15
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Lawrence  Steinman BA, M.D., Ph.D.', 'age': 75, 'title': 'Executive Chairman & Co-Founder', 'yearBorn': 1948, 'fiscalYear': 2022, 'totalPay': 250000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Tiago Reis Marques M.D., Ph.D.', 'age': 46, 'title': 'CEO & Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 539250, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel H. Schneiderman', 'age': 45, 'title': 'Chief Financial Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 327910, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Yassine  Bendiabdallah Ph.D.', 'age': 38, 'title': 'COO & Head of UK Clinics', 'yearBorn': 1985, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Graeme  Currie Ph.D.', 'title': 'Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.787
priceToSalesTrailing12Months§14.988542
currency§USD
dateShortInterest§1702598400
forwardEps§-0.71
exchange§NCM
quoteType§EQUITY
shortName§Pasithea Therapeutics Corp.
longName§Pasithea Therapeutics Corp.
firstTradeDateEpochUtc§1631712600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f19ed9f9-de4f-3b85-b823-68e1246ae624
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§9.628
grossMargins§0.76736
ebitdaMargins§0.0
trailingPegRatio§None
